Scholar Rock’s Apitegromab Filing Exposes the CMO Due Diligence Gap That Keeps Burning Sponsors
According to the FDA, it issued Warning Letter 320-26-20 to Catalent Indiana, LLC after a June 23 to July 14, 2025 inspection of its Bloomington, Indiana sterile drug facility resulted in an Official Action Indicated classification. Scholar Rock removed the facility from its apitegromab BLA refiling, with a Sept. 30, 2026 PDUFA date, and the FDA accepted the refile.
How this was made
The 30-second read
Why it matters
Scholar Rock’s apitegromab BLA refiling removed the Bloomington facility after the OAI, implying a manufacturing site substitution and resubmission workload (validation, comparability, rebuilt manufacturing section).
Market read
A manufacturing compliance event at a contract site led to a BLA refiling change for a late-stage rare-disease program, raising execution and resubmission risk into the PDUFA timeline.
What to watch
The piece does not quantify incremental delay versus the stated PDUFA date, nor does it provide financial guidance or explicit cost figures, limiting direct valuation impact.
Background
FDA issued Warning Letter 320-26-20 to Catalent Indiana, LLC after a June 23 to July 14, 2025 inspection, classified as Official Action Indicated (OAI).
Ticker impact
The article says Scholar Rock removed the Bloomington Catalent facility from its apitegromab BLA refiling after an FDA OAI warning letter.
Near-term sentiment risk, with magnitude dependent on how much delay/cost the company discloses next.
The text links an FDA OAI at a key fill-finish site to a BLA refiling and emphasizes resubmission rebuild work, which typically pressures development timelines and investor expectations.
Market effects
Highlights sponsor accountability for CMO GMP failures and may raise perceived execution risk for rare-disease programs reliant on fill-finish capacity.
Focuses on a Bloomington, Indiana sterile drug manufacturing site, implying localized scrutiny of contract manufacturing quality systems.
Reinforces FDA CGMP inspection and OAI-driven remediation dynamics that can affect global biologics development timelines.
Counterpoint
The article states the FDA accepted the refiled BLA and anchors the Sep 30, 2026 PDUFA date, suggesting the regulatory path may be intact despite added work.
Key entities
- companyScholar Rock
Sponsor of the apitegromab program; reportedly removed the Bloomington facility from its BLA refiling after the FDA OAI warning letter.
- productapitegromab
Spinal muscular atrophy treatment referenced with a PDUFA date of September 30, 2026.
- companyCatalent Indiana, LLC
Contract manufacturing facility operator at the Bloomington site that received the FDA OAI warning letter.
- regulatorFDA
Issued Warning Letter 320-26-20 and classified the inspection outcome as Official Action Indicated.
